4th generation non-small cell lung cancer targeted anti-cancer drug
TRX-221 U.S. FDA approves phase 1 clinical trial

At America AACR, announces poster of preclinical results of 4th
generation non-small cell lung cancer candidate material TRX-221

Holding the 1st clinical advisory committee in 4th generation non-
small cell lung cancer therapeutics candidate material TRX-221

MOU Concluding on development of
new anti-cancer drugs with Wuxi Apptech

Office on the 5th floor of Munjeong-dong
/ Bio-laboratory Expansion

Changing the corporate name to Therapex

Completing the spinoff of Organoid Division

Joint research agreement with Elgen
Therapeutics on developing PROTAC agents

Embarking on build-up of new drug R&D pipeline

Moving the headquarter and R&D center
to Songpa Area with expanded capacity

Appointing Dr. Koo Lee as CEO

Joint research agreement with Yonsei University Severance Biomedical
Science Institute on developing new drugs for lung cancer patients

Founded Interpark Bioconvergence Corp.